HOPKINTON, Mass., June 1, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading provider of tools and services for drug discovery and life sciences research, hosted its 2011 annual Customers Owners Group (COG 2011) meeting on May 17 and 18 at its Hopkinton headquarters. This thought-leadership conference brought together leaders in research, drug discovery, and diagnostics to discuss the technologies and discoveries that are transforming the detection and treatment of disease, and making personalized medicine a reality. More than 350 customers attended the event, which featured 45 presentations from researchers representing life sciences companies and institutions.
“COG 2011 was a tremendous congress, with presentation tracks focused on next generation sequencing, imaging & pathology, biomarkers discovery, molecular diagnostics, biologics & vaccines, and targeted small molecules, each of which is a critical enabling theme for personalized medicine. A key message from the meeting was the clear need for technological innovations in these areas that can enable the precision diagnostics and therapeutics that are required to achieve the vision of personalized medicine,” said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. “This event highlighted Caliper’s focus on innovation, collaboration, and culture as key cornerstones that define our efforts to extend and improve the quality of life and to truly place the patient first in the practice of medicine. Throughout the event, it was our privilege to motivate and provide inspiration to leading researchers from industry and academia, while also demonstrating how our technologies are having a profound impact on research applications.”
“One of the main reasons I am here today is the important collaborations between academy and industry are going to drive this revolution. We are in an era of technology-driven medicine,” said Dennis Ausiello, M.D., Chief of Medicine at Massachusetts General Hospital, Chief Scientific Officer of Partners Healthcare, and member of the Board of Directors of Pfizer and the Broad Institute, while delivering his keynote presentation about the advancements in research and technologies that will transform medicine. Dr. Ausiello cited specific examples where gene expression and sequencing technologies have improved the quality of patient care. “I am inspired personally by both the approach and the vision that Caliper has in helping deliver this revolution.”
Additional keynote presentations were provided by Go van Dam, M.D., Ph.D., the pioneering surgeon and Associate Professor at University Medical Center Groningen, who presented on the innovative clinical application of optical imaging and biomarker detection technologies during surgical procedures to significantly improve a patient’s prognosis, and by Stephan Schuster, Ph.D., Professor of Biochemistry and Molecular Biology, Pennsylvania State University and project leader for the South African Genome Project and the Wooly Mammoth Genome Project, who described the use of next generation sequencing to explore evolutionary diversity within mankind and of extinct and near-extinct organisms.
Caliper’s vision for personalized medicine includes several enabling technology themes that will revolutionize the practice of healthcare in the near future. Caliper’s COG events are organized into tracks that are closely aligned to these revolutionary themes: next generation sequencing, imaging and pathology, biomarkers discovery, molecular diagnostics, biologics and vaccines, and targeted small molecules.
Caliper extended its COG series, with upcoming events in Alameda, CA, USA on June 10, 2011 and in London, UK on September 14 and 15, 2011. For more details, and for presentations from previous COG events, please visit http://caliperls.com/support/caliper-owners-group.htm.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visit www.caliperLS.com.
Caliper is a registered trademark of Caliper Life Sciences, Inc.
SOURCE Caliper Life Sciences, Inc.
